Patent application number | Description | Published |
20080200532 | Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them - Provided are polymorphic forms of fluvastatin sodium and processes for their preparation. | 08-21-2008 |
20090118518 | Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them - Provided are crystalline forms of fluvastatin sodium and processes for their preparation. | 05-07-2009 |
20090143459 | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms - The present invention provides novel forms of atorvastatin designated Forms VI, VII, VIII, IX, IXa, X, XI, XII, XIV, XVI and XVII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin. | 06-04-2009 |
20090209611 | Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them - Provided are crystalline forms of fluvastatin sodium and processes for their preparation. | 08-20-2009 |
20090209763 | Novel Process For Making Bisphosphonic Acids Using Diluents Other Than Halogenated Hydrocarbons - Provided is a novel method of making bisphosphonic acids, e.g. risedronic acid, including the step of combining a carboxylic acid, phosphorous acid, and a halophosphorous compound in the presence of a diluent that is an aromatic hydrocarbon or a silicone fluid. When the diluent is an aromatic hydrocarbon, an inert support or ortho-phosphoric acid codiluent is advantageously included. | 08-20-2009 |
20100010221 | PROCESSES FOR PURIFYING VARENICLINE L-TARTRATE SALT AND PREPARING CRYSTALLINE FORMS OF VARENICLINE L-TARTRATE SALT - Processes for purifying Varenicline base or the L-tartrate salt thereof and for preparing Varenicline L-tartrate crystalline forms A and B are provided. | 01-14-2010 |
20100016579 | Crystalline forms of quetiapine hemifumarate - The present invention relates to novel crystalline forms of quetiapine hemifumarate, denominated quetiapine hemifumarate form II and quetiapine hemifumarate form III. These novel crystalline forms of quetiapine hemifumarate have been characterized by methods including x-ray powder diffraction (XRD), Fourier transform IR spectroscopy (FTIR), differential scanning calorimetry (DSC), and thermal gravimetric analysis (TGA). Methods for preparation of the novel crystalline quetiapine hemifumarate form II as its chloroform solvate and its dichloromethane solvate, form III as its chloroform solvate, and form I are provided. | 01-21-2010 |
20100016590 | NILOTINIB INTERMEDIATES AND PREPARATION THEREOF - Intermediates of Nilotinib were prepared, including, for example, 3-(trifluoromethyl-5-(4-methyl-1H-imidazole-1-yl)-benzeneamine; 3-(4-(pyridin-3-yl)pyrimidin-2-ylamino) -4-methylbenzoyl halogen dihydrochloride; and N-(3-Bromo-5-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide. Nilotinib.3HCl and its crystalline forms are also described. | 01-21-2010 |